Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q3 2016 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The transcript is about Ford's Q3 2016 earnings. The question asks about deals, orders, contracts, projects, customers, sites, or programs. Ford is an automaker, so "engagements" might refer to vehicle sales, but more likely to something like fleet orders, or perhaps autonomous vehicle partnerships, or something like that. However, the transcript focuses on financial results, product launches, market conditions, etc. There is no mention of deals, orders, contracts, or projects that are getting larger in size. The discussion is about vehicle sales, market share, pricing, production adjustments, etc. There is no mention of successive engagements of the same kind coming in at progressively larger size. The closest might be about the Super Duty launch, but that's a product launch, not a deal size escalation. The question specifically asks about "deals, orders, contracts, projects, customers, sites, or programs" that are individually bigger. Nothing in the transcript suggests that. Management talks about volume, market share, pricing, but not about the size of individual orders or contracts. There is no mention of average order size increasing, or customers starting at larger scale, etc. So the answer is NO. We must answer only YES or NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.